| Not Yet Recruiting | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692 | City of Hope Medical Center | Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Recruiting | Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation NCT05641935 | john eisenbrey | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335 | NiKang Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Active Not Recruiting | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer NCT03092856 | University of Southern California | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Active Not Recruiting | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer NCT02664883 | University of Southern California | — |
| Completed | Immunotherapy Study for Metastatic Renal Cell Cancer NCT02035358 | NewLink Genetics Corporation | Phase 1 |
| Terminated | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer NCT02542202 | University of Chicago | N/A |
| Active Not Recruiting | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, NCT02318771 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Terminated | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer NCT02170389 | Roswell Park Cancer Institute | N/A |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636 | Mayo Clinic | Phase 2 |
| Completed | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer NCT01727089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Ki NCT01688973 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01548482 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer NCT01239342 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After NCT01198158 | National Cancer Institute (NCI) | Phase 3 |
| Completed | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Grow NCT01141569 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastat NCT01061411 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer NCT00378703 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tu NCT00499135 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Su NCT00227760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat in Treating Patients With Kidney Cancer NCT00278395 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cance NCT00121251 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney NCT00126594 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer NCT00126490 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidne NCT00083109 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |